Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX33ZR)

• Drug Name: Mim8 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Haemophilia A	3B10.0	Phase 3	[1]

• Cross-matching ID: TTD Drug ID: DMX33ZR

Molecule-Related Drug Atlas

Drug(s) Targeting Coagulation factor IX (F9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Emicizumab	DM0AQ83	Factor VIII deficiency	3B10	Approved	[2]
Recombinant Factor IX	DMY7ESM	Bleeding disorder	GA20-GA21	Approved	[3]
CSL-654	DMZJGVL	Factor IX deficiency	3B11	Phase 3	[4]
RG6013	DMER75Y	Haemophilia A	3B10.0	Phase 3	[5]
AMT-061	DMSO02K	Haemophilia B	3B11.0	Phase 3	[6]
Fidanacogene elaparvovec	DMFZ81T	Haemophilia B	3B11.0	Phase 3	[7]
TTP889	DMCQARM	Blood forming organ disorder	JB64.1	Phase 2	[8]
AMT-060	DM7RNKM	Factor IX deficiency	3B11	Phase 1/2	[9]
SB-FIX	DMUP52Y	Haemophilia B	3B11.0	Phase 1/2	[10]
AAV2-hFIX16	DMIDEKB	Factor IX deficiency	3B11	Phase 1	[11]

Drug(s) Targeting Coagulation factor Xa (F10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apixaban	DM89JLN	Thrombosis	DB61-GB90	Approved	[12]
Rivaroxaban	DMQMBZ1	Deep vein thrombosis	BD71	Approved	[13]
DU-176b	DMCIJBH	Atrial fibrillation	BC81.3	Approved	[14]
Emicizumab	DM0AQ83	Factor VIII deficiency	3B10	Approved	[2]
BETRIXABAN	DM2C4RF	Venous thromboembolism	BD72	Approved	[15]
Lmw heparin	DMJPD06	Coagulation defect	3B10.0	Approved	[16]
Nadroparin calcium	DMBNKST	Coagulation defect	3B10.0	Approved	[17]
Fondaparinux sodium	DMWS3FH	Deep vein thrombosis	BD71	Approved	[18]
Danaparoid	DM6CLBN	Deep venous clot	BD71	Approved	[19]
Coagulation Factor IX	DM8HBJI	Haemophilia B	3B11.0	Approved	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor IX (F9)	TTFEZ5Q	FA9_HUMAN	Not Available	[1]
Coagulation factor Xa (F10)	TTCIHJA	FA10_HUMAN	Not Available	[1]

References

• [1] ClinicalTrials.gov (NCT05878938) Open-label Safety Study in Adults and Adolescents With Haemophilia A With and Without FVIII Inhibitors Switching Directly From Emicizumab Prophylaxis to NNC0365-3769 (Mim8) Prophylaxis. U.S.National Institutes of Health.
• [2] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [3] BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B. Ther Adv Hematol. 2014 Oct;5(5):168-80.
• [4] Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012 September 20; 120(12): 2405-2411.
• [5] Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014 Feb;12(2):206-13.
• [6] Clinical pipeline report, company report or official report of uniQure.
• [7] Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua. J Thromb Haemost. 2021 May;19(5):1212-1218.
• [8] Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008 Mar;6(3):457-63.
• [9] Phase I/II clinical trial of AMT-060 for treating hemophilia B. uniQure N.V.
• [10] ClinicalTrials.gov (NCT02695160) Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B. U.S. National Institutes of Health.
• [11] Assessing the potential for AAV vector genotoxicity in a murine model. Correction in: Blood. 2011 June 16; 117(24): 6739.
• [12] Pfizer. Product Development Pipeline. March 31 2009.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
• [15] Company report (Portola)
• [16] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [17] Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
• [18] Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
• [19] Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
• [20] Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.